CRIS Current Research Information System

MAZZELLA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.272
AS - Asia 10.508
EU - Europa 7.433
AF - Africa 610
SA - Sud America 479
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 3
Totale 30.322
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.178
VN - Vietnam 3.723
SG - Singapore 2.694
CN - Cina 2.209
GB - Regno Unito 1.997
IT - Italia 993
DE - Germania 965
SE - Svezia 849
HK - Hong Kong 560
FR - Francia 535
IN - India 492
RU - Federazione Russa 443
UA - Ucraina 407
BR - Brasile 330
IE - Irlanda 309
NL - Olanda 251
ZA - Sudafrica 193
JP - Giappone 185
EE - Estonia 160
CI - Costa d'Avorio 157
KR - Corea 135
CH - Svizzera 108
FI - Finlandia 102
TG - Togo 91
BG - Bulgaria 66
PH - Filippine 62
SC - Seychelles 61
BD - Bangladesh 58
AR - Argentina 56
CA - Canada 53
PL - Polonia 50
TH - Thailandia 49
JO - Giordania 48
ID - Indonesia 41
NG - Nigeria 40
GR - Grecia 38
BE - Belgio 36
AT - Austria 35
EC - Ecuador 35
TR - Turchia 35
TW - Taiwan 35
IQ - Iraq 31
PK - Pakistan 29
MX - Messico 27
ES - Italia 25
IR - Iran 22
SA - Arabia Saudita 21
EG - Egitto 16
LB - Libano 14
AU - Australia 13
MY - Malesia 11
PE - Perù 11
UZ - Uzbekistan 11
CL - Cile 10
LT - Lituania 10
CO - Colombia 9
CZ - Repubblica Ceca 9
ET - Etiopia 9
VE - Venezuela 9
IL - Israele 8
KE - Kenya 8
MA - Marocco 8
PY - Paraguay 8
RO - Romania 7
TN - Tunisia 7
DK - Danimarca 6
SI - Slovenia 6
BO - Bolivia 5
DZ - Algeria 5
HR - Croazia 5
SY - Repubblica araba siriana 5
UY - Uruguay 5
AO - Angola 4
KW - Kuwait 4
MD - Moldavia 4
MK - Macedonia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
PT - Portogallo 4
BH - Bahrain 3
LK - Sri Lanka 3
MM - Myanmar 3
NP - Nepal 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
BF - Burkina Faso 2
DO - Repubblica Dominicana 2
EU - Europa 2
JM - Giamaica 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LY - Libia 2
NI - Nicaragua 2
BW - Botswana 1
CR - Costa Rica 1
DM - Dominica 1
GD - Grenada 1
Totale 30.306
Salva come PNG Salva come JPEG
Città #
Singapore 1.872
Southend 1.800
Fairfield 1.357
Ashburn 1.162
Chandler 854
Ho Chi Minh City 835
Hanoi 745
Hong Kong 529
San Jose 526
Wilmington 515
Woodbridge 502
Houston 481
Santa Clara 474
Seattle 469
Dong Ket 439
Princeton 386
Cambridge 370
Dublin 307
Ann Arbor 303
Boardman 271
Beijing 264
Jacksonville 241
Bologna 227
Hefei 208
Lauterbourg 189
Nanjing 181
Westminster 177
Abidjan 157
Tokyo 154
Padova 149
Los Angeles 143
New York 129
Da Nang 119
Saint Petersburg 115
Dallas 114
Berlin 111
Haiphong 110
Buffalo 99
Lomé 91
Medford 87
Seoul 85
Milan 83
Bern 78
Helsinki 77
Jinan 76
Shenyang 75
Frankfurt am Main 74
Dearborn 67
Hebei 64
Sofia 62
Changsha 59
San Diego 59
Biên Hòa 56
Nanchang 56
Munich 52
Shanghai 52
Hải Dương 49
Amman 48
Thái Nguyên 48
Guangzhou 47
Bremen 45
Ha Long 45
Redondo Beach 45
Quận Bình Thạnh 44
Can Tho 42
Council Bluffs 42
Mülheim 41
Florence 40
Abeokuta 39
Tianjin 38
Des Moines 37
São Paulo 37
Bắc Ninh 33
Zhengzhou 32
Brussels 31
Johannesburg 31
Turin 31
Falkenstein 29
Hangzhou 29
Mahé 29
Jiaxing 28
Redwood City 28
London 26
Ninh Bình 26
Pune 26
Falls Church 25
Redmond 25
Bắc Giang 24
Chicago 24
Phoenix 24
Vinh 24
Wuhan 24
Amsterdam 23
Orem 23
Turku 23
Warsaw 23
Xi'an 23
Yubileyny 23
Shenzhen 22
Haikou 21
Totale 19.754
Salva come PNG Salva come JPEG
Nome #
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 608
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 510
Outcomes and survival after TIPS positioning: a single center experience 403
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 335
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 303
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 303
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 303
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 275
Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study 273
Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect 252
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 244
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 243
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 235
Berberine and its metabolites: Relationship between physicochemical properties and plasma levels after administration to human subjects 234
AISF position paper on liver disease and pregnancy 226
Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse. 222
The future of dual therapy for hepatitis C virus 221
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 218
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report 216
Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension 213
Adverse effects of proton pump inhibitors. 213
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 213
High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy 213
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 213
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 212
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 210
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 207
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 206
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 205
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 204
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 203
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 201
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 198
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis 197
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 197
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 197
The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis 196
Alisporivir for the treatment of chronic HCV 196
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 193
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 189
Utility of Doppler-Ultrasound and Liver Elastography in the Evaluation of Patients with Suspected Pregnancy-Related Liver Disease 185
Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature 185
Ribavirin for chronic hepatitis C: And the mystery goes on. 184
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 183
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 181
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 180
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 177
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 176
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 176
Colonic gallstone ileus treated with radiologically guided xtracorporeal shock wave lithotripsy followed by endoscopic extraction. 175
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 172
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 172
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 172
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 172
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 171
Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors 171
Small (≤3cm) Hepatocellular Carcinoma in Cirrhosis: the Role of Double Contrast Agents MR Imaging vs. Multi-Detector Row CT 170
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 170
Pharmacological modulation of MRP2 in primary biliary cirrhosis 169
Terapia cellulare in Epatologia 168
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 167
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 167
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 166
Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study 163
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 162
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 162
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 162
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 162
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 162
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 162
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management 161
Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome 161
Orthotopic liver transplantation (OLT): contribution of imaging and interventional radiology in preparing the transplantation and managing complications. Part 2: post-OLT complications and their treatment. 160
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 160
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project). 158
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 157
Indocyanine green clearance (ICG) as a predictor of 2-years clinical decompensation and mortality in patients with compensated liver cirrhosis 156
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis. 156
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients 156
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 155
Indocyanine green clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis. 155
Chemiluminescence measurement of autotaxin activity in human serum 154
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 154
Indocyanine green clearance as a marker of decompensation and clinically significant portal hypertension in patients with liver cirrhosis 154
Indocyanine Green Clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis 154
An unusual cause of weight loss in a young Caucasian man 153
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 153
Orthotopic liver transplantation (OLT): contribution of diagnostic imaging and interventional radiology in preparing the transplantation and managing complications. Part 1: Indications, surgical technique, diagnostic imaging and interventional radiology before transplantation from cadaveric and living donor. 152
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 151
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial 151
Fatty liver in pregnancy: a narrative review of two distinct conditions 151
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 150
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers 150
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 149
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 149
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 149
Safety of interferon beta treatment for chronic HCV hepatitis. 148
Breath tests with stable isotopes: have they a role in liver transplantation? 148
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy. 148
Reply 148
Totale 19.645
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.925
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.925
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.011 0 0 0 0 0 0 0 0 0 138 111 762
2021/20223.802 325 146 205 235 332 196 88 204 138 171 1.187 575
2022/20233.493 420 491 200 468 232 273 92 177 612 85 240 203
2023/20241.004 70 162 58 121 83 243 37 52 71 60 21 26
2024/20253.863 153 684 354 240 679 179 215 96 43 332 147 741
2025/20269.708 1.995 765 784 567 1.052 542 929 387 2.081 606 0 0
Totale 30.785